Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q3 Report 2019

November 7, 2019

Q2 Report 2019

August 7, 2019

Q1 Report 2019

May 9, 2019

Investor presentations

ObsEva Short Report 2018

1 2

Press Releases

ObsEva Announces Third Quarter 2019 Financial Results

press release

November 7, 2019

– Reports Update on Three Women’s Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the…

Read more

Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

press release

Company to Discontinue Current Nolasiban IVF Program   Geneva, Switzerland and Boston, MA – November 7, 2019 – ObsEva SA (NASDAQ:…

Read more

ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

press release

November 6, 2019

Geneva, Switzerland and Boston, MA –November 6, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing…

Read more
1 2 3 42

General Meetings

ObsEva Annual General Meeting 2019

May 8, 2019

Read more

ObsEva Annual General Meeting 2018

May 9, 2018

Read more
1 2

Upcoming Events

Year End 2019 Financial Results week of 02 March 2020

Event

March 2, 2020


Read more
 

Contacts

ObsEva Switzerland Office

+41 (0)22 552 3840


contact@obseva.ch

ObsEva U.S. Office

+1 857 972 9364


contact@obseva.ch

Media Switzerland & Europe

Christophe Lamps
Dynamics Group
+41 79 476 26 87

cla@dynamicsgroup.ch

Media United States

Marion Janic
RooneyPartners LLC
+1 212-223-4017

mjanic@rooneyco.com

Investor relations




ir@obseva.ch

Clinical studies




clinicaltrials@obseva.ch

HR Office

Charlotte Cadoux


charlotte.cadoux@obseva.ch

CEO Office

+41 (0)22 552 1550


shauna.dillon@obseva.ch

 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.